✦ LIBER ✦

An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma

✍ Scribed by Seiji Naito; Taiji Tsukamoto; Michiyuki Usami; Hiroyuki Fujimoto; Hideyuki Akaza

Book ID: 105993392
Publisher: Springer
Year: 2010
Tongue: English
Weight: 292 KB
Volume: 66
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-010-1262-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of personalized peptide va

Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients

✍ Shigetaka Suekane; Masaaki Nishitani; Masanori Noguchi; Yoshihiro Komohara; Taka 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

A Phase II trial of bryostatin-1 for pat

A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma

✍ Lance Pagliaro; Danai Daliani; Robert Amato; Shi-Ming Tu; Donnah Jones; Terry Sm 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 2 views

Phase II study of lenalidomide in patien

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma

✍ Toni K. Choueiri; Robert Dreicer; Brian I. Rini; Paul Elson; Jorge A. Garcia; Sn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB 👁 1 views

Phase II trial of topotecan in patients

Phase II trial of topotecan in patients with advanced renal cell carcinoma

✍ Teresa Murray Law; David H. Ilson; Robert J. Motzer 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 159 KB

Phase 2 trial of talactoferrin in previo

Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma

✍ Eric Jonasch; Walter M. Stadler; Ronald M. Bukowski; Teresa G. Hayes; Atul Varad 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

## Abstract ## BACKGROUND. Talactoferrin (TLF), a recombinant form of human lactoferrin (hLF), is an immunomodulatory iron‐binding glycoprotein first identified in breast milk. Its immunomodulatory functions include activation of natural killer (NK) and lymphokine‐activated killer cells and enhanc

Phase 1 dose-escalation trial of tremeli

Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

✍ Brian I. Rini; Mark Stein; Pat Shannon; Simantini Eddy; Allison Tyler; Joe J. St 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 273 KB 👁 2 views